Drug Name: Omalizumab-igec

Brand Name: Omlyclo®

Medicine Use: Add-on therapy/long-term control

Type of Medicine: Biologic

Form: Injection

Prescribing Info: Omlyclo (omalizumab-igec) injection prescribing information insert

Notes: OMLYCLO® (omalizumab-igec) is biosimilar to XOLAIR® (omalizumab). XOLAIR is also approved for chronic rhinosinusitis with nasal polyposis and chronic spontaneous urticaria (chronic hives).

Possible Side Effects:
Asthma (adult and adolescent patients, older than 12 years)
Joint pain
Pain (general)
Leg pain
Fatigue
Dizziness
Fracture
Arm pain
Itchy skin
Dermatitis
Earache

Asthma (pediatric patients, ages 6-12)
Common cold
Headache
Fever
Upper abdominal pain
Strep throat
Ear infection
Stomach flu
Arthropod bites
Nosebleed

Chronic Rhinosinusitis with Nasal Polyps:
Headache
Injection site reaction
Joint pain
Upper abdominal pain
Dizziness

IgE-Mediated Food Allergy:
Injection site reactions
Fever

Chronic Spontaneous Urticaria:
Nausea
Common cold
Sinus Infection
Upper respiratory tract infection
Viral upper respiratory tract infection
Joint pain
Headache
Cough